Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma.
In this pilot clinical trail the efficacy of intralesional low-dose human recombinant interferon-gamma was investigated in seven outpatients with nodular basal cell carcinoma. There was no antitumor response in any case. Toxic side effects were minimal. All tumors were excised surgically 8 weeks after completion of therapy.
Tank
B
B
Department of Dermato-Venereology, Erasmus University, Rotterdam, The Netherlands.
Habets
J M
JM
Naafs
B
B
Damsma
O
O
Stolz
E
E
van Joost
T
T
D000368:Aged; D002280:Basal Cell Carcinoma / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000628:therapy*
D007371:Interferon-gamma